"Cancers persist by adapting to live in new tissues and organs, and we found that pancreatic tumors use PCSK9 to adapt as they spread," said Dr. Perera. She noted that the research provides a potential roadmap for fighting metastatic growth by targeting the very pathways the cells use to survive their journey through the body. By manipulating how cells acquire their cholesterol, clinicians might one day be able to trap cancer cells in a metabolic state that makes them unable to survive outside of the primary tumor site, or at least make them more vulnerable to existing treatments.
The study also highlights the importance of collaborative, large-scale data projects like the Broad Institute’s MetMap. By providing a baseline of how different cancers behave, such resources allow researchers to move more quickly toward identifying the specific proteins and genes responsible for that behavior. This study was a multi-disciplinary effort, supported by several major scientific organizations. Funding was provided in part by the National Institutes of Health (NIH), the National Science Foundation (NSF), and the American Association for Cancer Research (AACR), reflecting the high level of priority placed on finding new avenues for pancreatic cancer intervention.
While the research is currently centered on the biological mechanisms of PCSK9 in a laboratory setting, the fact that PCSK9 inhibitors are already FDA-approved and widely used to treat high cholesterol in cardiovascular patients provides an intriguing starting point for future clinical investigations. While it is too early to say whether existing cholesterol drugs could be repurposed to treat pancreatic cancer, the UCSF study provides the essential scientific foundation needed to explore such possibilities.
As the medical community continues to grapple with the complexities of pancreatic cancer, the discovery of the PCSK9 switch represents a vital step forward. It moves the understanding of metastasis away from a model of random spread toward a more predictable model of metabolic adaptation. By viewing cancer not just as a mass of growing cells, but as a population of highly adaptable organisms that must solve specific environmental problems to survive, researchers are finding new weaknesses in an old and deadly foe. The ability to potentially "reroute" or disable the metabolic GPS of a cancer cell offers a glimmer of hope for more effective therapies in the years to come.
